According to GlobalData’s medical device pipeline database, 88 Tissue Engineered Skin Substitutes devices are in various stages of development globally. GlobalData’s report Tissue Engineered – Skin Substitutes provides an overview of the segment’s pipeline landscape and offers detailed analysis of its products. Buy the report here.

Smarter leaders trust GlobalData

Of these devices, 35 are in active development, while the remaining 53 are in an inactive stage of development. There are 18 products in the early stages of development, and the remaining 17 are in the late stages of development.

Tissue engineering for wound care management is the use of mechanical and chemical processing of materials to manufacture products that may substitute or replace all or some components that make up a normal skin (e.g. epidermis and/or dermis, cells and matrix). They can be derived from human tissue (autologous or allogenic), non-human tissue (enographic), a composite, or synthetic materials. Acellular or cellular may consist of a synthetic epidermis and a collagen-based dermis to encourage formation of new tissue. In products that have a synthetic epidermis, this may be a temporary wound covering. This category consists of cellular skin substitutes and acellular skin substitutes.

Innovations in the medical devices sector are linked to the development of new approaches, processes, or technologies for treating, diagnosing, and managing disease in response to demand from healthcare for better patient outcomes and reduce healthcare costs.

Based on an analysis of GlobalData’s Medical Intelligence Center pipeline product database, these actively developed Tissue Engineered Skin Substitutes pipeline devices are all expected to be approved within the next ten years.

Currently, private organizations, public entities and institutions are working on the development of Tissue Engineered Skin Substitutes devices. Overall, most of these Tissue Engineered Skin Substitutes pipeline devices are being developed by private entities.

Key players involved in the active development of Tissue Engineered Skin Substitutes include Stratatech, PlasMedica Technologies, Organogenesis, RegenETP, MiMedx Group, Acro Biomedical, Regenicin, PolyNovo Biomaterials, Tissue Regenix Group and Sree Chitra Tirunal Institute for Medical Sciences & Technology.

For a complete picture of the developmental pipeline for Tissue Engineered Skin Substitutes devices, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. 

The medical devices pipeline data used in this article were obtained from the Medical Pipeline Products Database of GlobalData’s Medical Intelligence Center. The Pipeline Products database is a is a comprehensive source of information on medical devices, it covers 39K products which are in development stage and intended for diagnosis, treatment, and management of diseases/conditions/symptoms directly or indirectly. The pipeline products included in the database are sourced from reliable and authenticated sources, such as company websites, SEC filings, conference presentations, analyst presentations, news releases, clinical trial registries, and grants. The information is collected by following systematic research techniques and proprietary methodology.